These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 21470062

  • 1. Paclitaxel poliglumex for ovarian cancer.
    Galic VL, Wright JD, Lewin SN, Herzog TJ.
    Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062
    [Abstract] [Full Text] [Related]

  • 2. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group Study.
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF.
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
    Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM.
    Anticancer Drugs; 2010 Apr; 21(4):433-8. PubMed ID: 20016365
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.
    Clin Cancer Res; 2005 Nov 01; 11(21):7834-40. PubMed ID: 16278406
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
    Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV.
    Gynecol Oncol; 2006 Feb 01; 100(2):437-8. PubMed ID: 16226797
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
    Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S.
    Cancer Chemother Pharmacol; 2000 Feb 01; 46(5):416-22. PubMed ID: 11127947
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF.
    J Natl Compr Canc Netw; 2004 Sep 01; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
    Miolo G, Bidoli E, Lombardi D, Santeufemia DA, Capobianco G, Dessole F, Scalone S, Spazzapan S, Sorio R, Tabaro G, Veronesi A.
    Arch Gynecol Obstet; 2012 Feb 01; 285(2):499-503. PubMed ID: 21735184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.